Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

NCT04490915 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

182

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Adrenal Hyperplasia

Interventions

DRUG: Crinecerfont
DRUG: Placebo

Sponsor

Neurocrine Biosciences